Samsung Asset Management's 'KoAct BioHealthcare Active' ETF Records High Returns
With rising investor interest in the bio-healthcare sector due to the U.S. interest rate cut, Samsung Asset Management's 'KoAct BioHealthcare Active' ETF is gaining attention. This ETF has recorded a 24.3% return over the past three months, the highest among domestic stock-type active ETFs, drawing significant interest from investors. Its key investment stocks include Alteogen, Ligchem Bio, and Samsung Biologics, with respective proportions of 13.74%, 10.72%, and 9.89%.
The bio-healthcare industry is expected to continue its growth alongside the interest rate cuts, with increased operating profits and new drug development clinical trial results expected to have a positive impact. Some analysts attribute this to the recent 50bp interest rate cut by the U.S. Federal Reserve.
Additionally, the September FOMC meeting confirmed the interest rate cut, attracting investors not only to the bio-healthcare sector but also to the Indian market. The Indian stock market saw a rise of over 20% last year, and many domestic investors are considering investing in the Indian market through ETFs, highlighting the global interest in this emerging market.
Related ETF
Related News
KoAct Bio Healthcare Active, 3-month Return Rate Active ETF Ranked 1st - Maeil Business NewspaperThanks to the interest rate cuts in the U.S., investors' interest in the bio healthcare sector is increasing, and the resulting performance is elevating expectations. Samsung Active Asset Management announced on the 24th that 'KoAct Bio Healthcare Active' recorded a 3-month return rate of 24.3%, marking the highest return rate among domestic stock-type active ETFs. This product also achieved a 1-month return of 8.6% and a 6-month return of 25.7%.
Related ETF
Samsung Active Asset Management 'KoAct BioHealthcare Active Ranked 1st in 3-Month Return Rate' - Metro News - Valuable Information for the Middle Class and Ordinary PeopleSamsung Active Asset Management announced on the 24th that 'KoAct BioHealthcare Active' achieved a 3-month return rate of 24.3%, the highest among domestic equity active ETFs. KoAct BioHealthcare Active is the first active ETF in Korea to invest in the biohealthcare sector globally.
Related ETF
[How Money] What is the recent trend in the ETF market? - SBS BizInvestment know-how money show 'How Money' - Sung-Jin Jung / Head of ETF Business Division at Kiwoom Investment Management. After the interest rate cut became certain at the Fed's September FOMC, investors focused on the bio & healthcare sectors, which were considered beneficiaries. Due to the highly volatile market, a lot of investment has flocked to ETFs. Moreover, with the upcoming U.S. presidential election, China is being considered as an alternative investment destination...
AlteoGen, Ligachem, and Samsung BioLogics lead a strong bio rally - Smart TodaySmart Today = Reporter Kim Se-hyung Amid a bio stock rally following the big cut (interest rate cut) in the US, the KoAct BioHealthcare Active ETF's three-month return has reached a whopping 25%. This is due to the significant weighting of leading bio stocks such as AlteoGen, Ligachem Bio, and Samsung BioLogics.
Related ETF